Our company has been recognised as one of the TOP 100 best startups of 2023, according to the Association of Science and Technology Parks of Spain (APTE).
This distinction rewards the most innovative projects of its 51 science and technology parks, and focuses on different areas, including biotechnology.
Our company has been chosen for its leadership in research and development in NLRP3 and inflammatory processes, with a special emphasis on sepsis, as well as other diseases related to these processes, such as cancer and diseases of the central nervous system.
Congratulations to APTE for all its work in supporting the entrepreneurial capacity that is developed in these environments, as well as for facilitating the knowledge of projects like ours among potential investors, aware of the contribution of our companies to innovation, investigation and the development of solutions and services that are essential for our society.
Thank you on behalf of the entire #VivainVitro team.